Tilomisole

Tilomisole (WY-18,251) is an experimental drug which acts as an immunomodulator and has been studied for the treatment of some forms of cancer.[1][2]

Tilomisole
Names
Preferred IUPAC name
[3-(4-Chlorophenyl)[1,3]thiazolo[3,2-a] [1,3]benzimidazol-2-yl]acetic acid
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
KEGG
UNII
  • InChI=1S/C17H11ClN2O2S/c18-11-7-5-10(6-8-11)16-14(9-15(21)22)23-17-19-12-3-1-2-4-13(12)20(16)17/h1-8H,9H2,(H,21,22)
  • Clc4ccc(c1c(sc2nc3ccccc3n12)CC(=O)O)cc4
Properties
C17H11ClN2O2S
Molar mass 342.80
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

It can also be seen to contain the arylacetic acid moiety that is endemic to many NSAIDs, e.g. ibufenac.

References

  1. Fenichel RL, Alburn HE, Schreck PA, Bloom R, Gregory FJ (1980). "Immunomodulating and antimetastatic activity of 3-(p-chlorophenyl) thiazolo[3,2-a]benzimidazole-2-acetic acid (Wy-18,251, NSC 310633)". Journal of Immunopharmacology. 2 (4): 491–508. doi:10.3109/08923978009026408. PMID 6970786.
  2. Dillman RO, Ryan KP, Dillman JB, Shawler DL, Maguire R (March 1992). "WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients". Molecular Biotherapy. 4 (1): 10–4. PMID 1385709.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.